NATCO PHARMA
|
NATCO PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 39.19 | 9.32 | 24.16 | 25.32 | 35.31 |
| CEPS(Rs) | 48.17 | 17.13 | 30.65 | 30.65 | 39.64 |
| DPS(Rs) | 5.50 | 4.50 | 5.25 | 6.75 | 6.25 |
| Book NAV/Share(Rs) | 267.06 | 233.44 | 224.88 | 206.04 | 189.49 |
| Tax Rate(%) | 17.01 | 15.92 | 23.67 | 19.45 | 22.11 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 31.64 | 11.89 | 28.97 | 28.31 | 34.79 |
| EBIT Margin(%) | 30.42 | 9.92 | 28.45 | 28.68 | 36.94 |
| Pre Tax Margin(%) | 29.91 | 9.12 | 27.81 | 27.63 | 36.10 |
| PAT Margin (%) | 24.83 | 7.67 | 21.23 | 22.26 | 28.12 |
| Cash Profit Margin (%) | 30.51 | 14.10 | 26.84 | 27.11 | 31.66 |
| Performance Ratios | |||||
| ROA(%) | 13.29 | 3.43 | 9.43 | 10.30 | 16.02 |
| ROE(%) | 15.66 | 4.06 | 11.27 | 12.71 | 19.75 |
| ROCE(%) | 18.06 | 4.86 | 13.99 | 14.82 | 23.71 |
| Asset Turnover(x) | 0.54 | 0.45 | 0.44 | 0.46 | 0.57 |
| Sales/Fixed Asset(x) | 0.89 | 0.76 | 0.86 | 1.07 | 1.47 |
| Working Capital/Sales(x) | 1.24 | 1.25 | 1.15 | 1.25 | 1.41 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.13 | 1.32 | 1.16 | 0.93 | 0.68 |
| Receivable days | 93.53 | 85.10 | 84.44 | 93.77 | 91.36 |
| Inventory Days | 95.32 | 128.47 | 118.77 | 96.38 | 77.28 |
| Payable days | 133.18 | 106.38 | 151.52 | 243.26 | 266.65 |
| Valuation Parameters | |||||
| PER(x) | 14.38 | 81.30 | 34.16 | 19.99 | 16.19 |
| PCE(x) | 11.70 | 44.21 | 26.92 | 16.51 | 14.42 |
| Price/Book(x) | 2.11 | 3.24 | 3.67 | 2.46 | 3.02 |
| Yield(%) | 0.98 | 0.59 | 0.64 | 1.33 | 1.09 |
| EV/Net Sales(x) | 3.66 | 7.21 | 7.33 | 4.94 | 5.03 |
| EV/Core EBITDA(x) | 9.52 | 38.67 | 21.19 | 13.71 | 11.39 |
| EV/EBIT(x) | 11.30 | 63.75 | 25.37 | 16.03 | 12.49 |
| EV/CE(x) | 1.75 | 2.74 | 3.14 | 2.06 | 2.45 |
| M Cap / Sales | 3.80 | 7.11 | 7.34 | 4.81 | 4.98 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 39.20 | -5.23 | 7.16 | -8.57 | -4.13 |
| Core EBITDA Growth(%) | 186.95 | -48.93 | 2.87 | -25.41 | -4.52 |
| EBIT Growth(%) | 298.54 | -62.91 | 0.46 | -30.07 | -6.49 |
| PAT Growth(%) | 320.76 | -61.57 | -3.43 | -28.69 | -7.59 |
| EPS Growth(%) | 320.76 | -61.44 | -4.58 | -28.30 | -6.43 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.03 | 0.09 | 0.06 | 0.08 | 0.11 |
| Current Ratio(x) | 4.39 | 3.50 | 4.46 | 3.39 | 3.22 |
| Quick Ratio(x) | 3.35 | 2.49 | 3.04 | 2.63 | 2.50 |
| Interest Cover(x) | 60.44 | 12.42 | 44.58 | 27.45 | 43.73 |
| Total Debt/Mcap(x) | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 |
Compare Financial Ratios of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹18,247.6 Cr | 1.1% | 2.1% | 76.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹367,026.0 Cr | 0.5% | -5.7% | 55.1% | Stock Analytics | |
| CIPLA | ₹114,925.0 Cr | 1.1% | -4.4% | 55.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹105,128.0 Cr | -0.7% | 9.4% | 21.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹105,109.0 Cr | 0.1% | 1.1% | 28.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹102,736.0 Cr | 6% | 2.8% | 93.1% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 1.1% |
2.1% |
76.9% |
| SENSEX | 0.2% |
-0.2% |
20.9% |
You may also like the below Video Courses
